Literature DB >> 10741697

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.

S R Lakhani1, B A Gusterson, J Jacquemier, J P Sloane, T J Anderson, M J van de Vijver, D Venter, A Freeman, A Antoniou, L McGuffog, E Smyth, C M Steel, N Haites, R J Scott, D Goldgar, S Neuhausen, P A Daly, W Ormiston, R McManus, S Scherneck, B A Ponder, P A Futreal, J Peto, D Stoppa-Lyonnet, Y J Bignon, M R Stratton.   

Abstract

Breast cancers arising in carriers of mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, differ histologically from each other and from breast cancers unselected for a family history. However, a substantial proportion of families with multiple cases of breast cancer is not attributable to these two genes (non-BRCA1/2 families). We have now characterized the pathology of 82 breast cancers from non-BRCA1/2 families. Breast cancers in non-BRCA1/2 families were of lower grade (P = 0.0018), showed fewer mitoses (P < 0.0001), less nuclear pleomorphism (P = 0.0014), less lymphocytic infiltrate (P < 0.0001), a lesser extent of the tumor with a continuous pushing margin (P = 0.004), a lesser extent of the tumor composed of solid sheets of cells (P = 0.0047), less necrosis (P = 0.002), and wereparison with BRCA2 tumors, non-BRCA1/2 tumors were lower grade (P = 0.017) and exhibited less pleomorphism (P = 0.01) and more tubule formation (P = 0.05). In comparison with control breast cancers unselected for a family history of the disease, non-BRCA1/2 tumors were of significantly lower grade (P = 0.001), showed less pleomorphism (P = 0.0002), and had a lower mitotic count (P = 0.003). The results indicate that non-BRCA1/2 breast cancers differ histologically from both BRCA1 and BRCA2 breast cancers and are overall of lower grade. They also suggest that non-BRCA1/2 breast cancers differ from nonfamilial breast cancers, but these differences may be attributable to various types of bias.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741697

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  55 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Evaluation for Kienböck Disease Familial Clustering: A Population-Based Cohort Study.

Authors:  Nikolas H Kazmers; Zhe Yu; Tyler Barker; Tyler Abraham; Robin Romero; Michael J Jurynec
Journal:  J Hand Surg Am       Date:  2019-11-22       Impact factor: 2.230

3.  Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer.

Authors:  Ee Ming Wong; Melissa C Southey; Stephen B Fox; Melissa A Brown; James G Dowty; Mark A Jenkins; Graham G Giles; John L Hopper; Alexander Dobrovic
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-26

Review 4.  Genome-wide association studies in the genetics of asthma.

Authors:  Saffron A G Willis-Owen; William O Cookson; Miriam F Moffatt
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

5.  High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Authors:  Banu Arun; Kristen J Vogel; Adriana Lopez; Mike Hernandez; Deann Atchley; Kristine R Broglio; Christopher I Amos; Funda Meric-Bernstam; Henry Kuerer; Gabriel N Hortobagyi; Constance T Albarracin
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

6.  The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers.

Authors:  R Kaas; R Kroger; J H C L Hendriks; A P E Besnard; W Koops; F A Pameijer; W Prevoo; C E Loo; S H Muller
Journal:  Eur Radiol       Date:  2004-04-09       Impact factor: 5.315

7.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.

Authors:  Robert M W Hofstra; Amanda B Spurdle; Diana Eccles; William D Foulkes; Niels de Wind; Nicoline Hoogerbrugge; Frans B L Hogervorst
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

9.  Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls.

Authors:  Marise R Heerma van Voss; Petra van der Groep; Jos Bart; Elsken van der Wall; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-04-16       Impact factor: 4.430

10.  BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.

Authors:  M Yan; M Rayoo; E A Takano; H Thorne; S B Fox
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.